AlzeCure at Redeye Life Science Days – December 3
October 9, 2025
AlzeCure will participate in Redeye Life Science Days, December 3, 2025 Presentations will be live-streamed.
AlzeCure at LSX conference 17 November
October 9, 2025
AlzeCure will participate in the LSX conference, 17th of November in London
AlzeCure at BioEurope 3-5 November
October 9, 2025
AlzeCure will participate in Bio-Europe, 3 – 5 November in Vienna.
AlzeCure at Redeye Neurology day October 15
October 9, 2025
AlzeCure Pharma to Present at Redeye Neurology Day October 15 AlzeCure will participate at Redeye Neurology Day on October 15 at 11:40 CET, where CEO Martin Jönsson ...
AlzeCure at NLS days
October 9, 2025
AlzeCure Pharma will participate in Nordic Life Science Days, 13 – 14 October in Gothenburg, Sweden.
AlzeCure at Bio Japan
October 8, 2025
AlzeCure Pharma is participating in Bio Japan October 8 – 10, 2025, in Yokohama, presenting the company & projects, meeting with partners, investors and ph...
AlzeCure presentation by CEO Martin Jönsson
September 26, 2025
CEO Martin Jönsson presents AlzeCure Pharma, the project pipeline and the science behind it. See and hear the presentation here and the pdf version is available her...
Interview at Redeye about new results for the pain project ACD440
September 17, 2025
Interview at Redeye about new results for the pain project ACD440 directed at neuropathic pain, the projects orphan drug status at the FDA & the outlicensing st...
AlzeCure Pharma nominated as finalist to European LifeStars Awards
September 11, 2025
AlzeCure has been nominated as finalist for the 2025 European Lifestars Awards in the category Post IPO Raise of The Year. The AlzeCure issue that has lead to the no...
AlzeCure presents at NeuPSIG 2025 – International Congress on Neuropathic Pain
September 4, 2025
AlzeCure presents new data for both ACD440 and ACD137 at NeuPSIG 2025 – International Congress on Neuropathic Pain Read more about the data presented for ACD440 here...
Seminar on Painless ACD440 against erytheromelalgia and the opportunities within the orphan drug market and for erytheromelalgia.
August 27, 2025
Presentation See webcast:
AlzeCure achieved an oversubscribed rights issue, July 2025
July 24, 2025
”We thank our principal owners and other existing shareholders for the continued strong support, and would also like to welcome new shareholders to AlzeCure. We also...
Nordic Asia Life-science Summit
June 2, 2025
CEO, Martin Jönsson attended at Nordic Asia Life-science Summit on May 28th, 2025. Scan the QR-code, to read the presentation
AlzeCure participated at the 3rd Swedish Meeting for Alzheimer Research
April 10, 2025
Several from AlzeCure participated at the Swedish Meeting for Alzheimer Research, April 10, 2025, where also Dr. Cristina Parrado-Fernández, Senior Scientist present...
AlzeCure receives EU grant for Phase 2 clinical trial of NeuroRestore ACD856 for Alzheimer’s disease
February 17, 2025
“The grant we received from the European Innovation Council is a strong validation of NeuroRestore ACD856, which has a unique pharmacological mechanism that en...
AlzeCure´s CEO, Martin Jönsson and CSO, Johan Sandin attend JP Morgan in San Francisco, January 13 – 16, 2025
February 4, 2025
Read more: https://www.biocentury.com/jpm-guide
AlzeCure presents new anti-inflammatory data with NeuroRestore ACD856 at the Alzheimer’s conference CTAD
October 17, 2024
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer&#...